Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

161.20
+1.771.11%
Post-market: 165.324.12+2.56%19:58 EST
Volume:4.74M
Turnover:773.47M
Market Cap:34.87B
PE:-17.63
High:169.51
Open:161.61
Low:160.22
Close:159.43
52wk High:224.31
52wk Low:69.50
Shares:216.29M
Float Shares:204.27M
Volume Ratio:1.74
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.1445
EPS(LYR):-5.9502
ROE:-93.56%
ROA:-32.13%
PB:14.52
PE(LYR):-27.09

Loading ...

Revolution Medicines (RVMD) Reports Fresh RASONQUE Data, Is The Stock Priced For Perfection?

Simply Wall St.
·
15 hours ago

Does First Line Pancreatic Data Change The Bull Case For Revolution Medicines (RVMD)?

Simply Wall St.
·
Yesterday

Movement Alert|Revolution Medicines, Inc. Intraday Rise 4.21% in Regular Trading, Updated Rasonque clinical data lifted sentiment

Market Focus
·
Nov 20

Movement Alert|Revolution Medicines, Inc. Pre-Market Rise 4.1%, EU Approves Rasonque for Metastatic Pancreatic Cancer

Market Focus
·
Nov 20

Revolution Medicines presents updated Phase 1/2 data for RASONQUE

TIPRANKS
·
Nov 20

Revolution Medicines' Rasonque-Chemotherapy Combination Shows 60.7% Response Rate in Pancreatic Cancer Trial

Reuters
·
Nov 20

Movement Alert|Revolution Medicines, Inc. Intraday Rise 4.11% in Regular Trading, EU approval of Rasonque supports sentiment

Market Focus
·
Nov 19

Revolution Medicines Senior Advisor to CEO Stephen Michael Kelsey Reports Sale of $4.56 Million in Common Shares

Reuters
·
Nov 19

Revolution Medicines Price Target Maintained with a $350.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 17

Revolution Medicines says EC approves Rasonque in metastatic pancreatic cancer

TIPRANKS
·
Nov 17

EU Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer

Reuters
·
Nov 17

European Commission Approves Revolution Medicines’ Rasonque® (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Nov 17

Revolution Medicines - Rasonque Marketing Authorization Does not Apply in UK or Switzerland

THOMSON REUTERS
·
Nov 17

Revolution Medicines Price Target Cut to $247.00/Share from $272.00 by Morgan Stanley

Dow Jones
·
Nov 14

Movement Alert|Revolution Medicines, Inc. Falls 4.14% in Regular Trading, Post-Earnings Valuation Digestion Pressure Persists

Market Focus
·
Nov 13

Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Nov 13

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports $162,200 Common Share Disposal

Reuters
·
Nov 13

US FDA Shelves Commissioner's Voucher Program for Speedy Drug Reviews, Sources Say

Reuters
·
Nov 12

Revolution Medicines (RVMD) Stock Dropped, So What Is Driving Attention Now?

Simply Wall St.
·
Nov 12

Movement Alert|Revolution Medicines, Inc. Falls 4.13% in Regular Trading, Post-Earnings Valuation Digestion Pressure Persists

Market Focus
·
Nov 11